CN112955174A - 融合剂脂质体组合物和其用途 - Google Patents

融合剂脂质体组合物和其用途 Download PDF

Info

Publication number
CN112955174A
CN112955174A CN201980058212.6A CN201980058212A CN112955174A CN 112955174 A CN112955174 A CN 112955174A CN 201980058212 A CN201980058212 A CN 201980058212A CN 112955174 A CN112955174 A CN 112955174A
Authority
CN
China
Prior art keywords
fusion agent
liposome
cell
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980058212.6A
Other languages
English (en)
Chinese (zh)
Inventor
G.A.冯马尔特扎恩
J.R.鲁本斯
J.M.米尔维德
M.T.米
N.F.戈登
J.V.沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of CN112955174A publication Critical patent/CN112955174A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980058212.6A 2018-07-09 2019-07-09 融合剂脂质体组合物和其用途 Pending CN112955174A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862695650P 2018-07-09 2018-07-09
US201862695537P 2018-07-09 2018-07-09
US62/695,650 2018-07-09
US62/695,537 2018-07-09
US201862767241P 2018-11-14 2018-11-14
US201862767261P 2018-11-14 2018-11-14
US62/767,241 2018-11-14
US62/767,261 2018-11-14
US201962848284P 2019-05-15 2019-05-15
US201962848305P 2019-05-15 2019-05-15
US62/848,284 2019-05-15
US62/848,305 2019-05-15
PCT/US2019/040978 WO2020014209A1 (en) 2018-07-09 2019-07-09 Fusosome compositions and uses thereof

Publications (1)

Publication Number Publication Date
CN112955174A true CN112955174A (zh) 2021-06-11

Family

ID=67659932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058212.6A Pending CN112955174A (zh) 2018-07-09 2019-07-09 融合剂脂质体组合物和其用途

Country Status (12)

Country Link
US (2) US12378578B2 (https=)
EP (1) EP3820509A1 (https=)
JP (1) JP7588578B2 (https=)
KR (1) KR20210043574A (https=)
CN (1) CN112955174A (https=)
AU (1) AU2019301053A1 (https=)
BR (1) BR112021000145A2 (https=)
CA (1) CA3105953A1 (https=)
IL (1) IL279897A (https=)
MX (1) MX2021000308A (https=)
SG (1) SG11202100071YA (https=)
WO (1) WO2020014209A1 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113960317A (zh) * 2021-08-19 2022-01-21 深圳市辅酶医科技有限公司 一种测量生物样品中nad+浓度的生物传感器及方法
CN113969264A (zh) * 2021-11-29 2022-01-25 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN113975285A (zh) * 2021-08-27 2022-01-28 南京大学 Ggpp结合并变构激活人源fbp1在制备抗肝细胞癌药物中的应用
CN114292319A (zh) * 2021-12-31 2022-04-08 中国科学院遗传与发育生物学研究所 水稻ETFβ基因在调控植物育性中的应用
CN114875087A (zh) * 2022-04-27 2022-08-09 河北维达康生物科技有限公司 以β-吲哚基丙氨酸为底物合成5-羟基β-吲哚基丙氨酸的方法及其应用
CN115851632A (zh) * 2022-08-25 2023-03-28 华中农业大学 一种漆酶突变体及其应用
CN116970650A (zh) * 2023-09-22 2023-10-31 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法
CN119213133A (zh) * 2022-05-16 2024-12-27 上海天泽云泰生物医药有限公司 用于治疗i型戊二酸尿症的重组aav载体
WO2025256433A1 (zh) * 2024-06-14 2025-12-18 四川大学华西医院 一种转铁蛋白受体1靶向性糖苷水解酶复合体的制备方法及应用

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7657726B2 (ja) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2021016075A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
IL296024A (en) 2020-03-04 2022-10-01 Flagship Pioneering Innovations Vi Llc Methods and compositions for modulating a genome
JP2023521663A (ja) * 2020-03-31 2023-05-25 サナ バイオテクノロジー，インコーポレイテッド 標的化脂質粒子及び組成物ならびにその使用
EP3913060A1 (en) * 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
US20230210959A1 (en) * 2020-06-16 2023-07-06 Novel Pharma Inc. Composition for treatment of glutaric aciduria and administration method therefor
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
EP4274901A1 (en) * 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
IL307544A (en) 2021-04-08 2023-12-01 Sana Biotechnology Inc Cd8-specific antibody constructs and compositions thereof
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2023015217A1 (en) 2021-08-04 2023-02-09 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023023467A1 (en) * 2021-08-17 2023-02-23 Interius Biotherapeutics, Inc. Nucleic acid molecules and methods of using the same
JP2024533311A (ja) 2021-09-08 2024-09-12 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ゲノムを調節するための方法及び組成物
US20240342314A1 (en) * 2021-09-30 2024-10-17 The Board Of Regents Of The University Of Texas System Slc13a5 gene therapy vectors and uses thereof
CN114032239B (zh) * 2021-10-28 2024-06-21 北京美康基免生物科技有限公司 一种组织特异启动子及其应用
EP4426331A1 (en) 2021-11-02 2024-09-11 University of Rochester Tcf7l2 mediated remyelination in the brain
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158487A1 (en) * 2022-02-15 2023-08-24 The Broad Institute, Inc. Cell-type specific membrane fusion proteins
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4641202A3 (en) 2022-05-25 2026-01-21 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulation of immune responses
US20250319115A1 (en) 2022-05-25 2025-10-16 Flagship Pioneering Innovations Vii, Llc Compositions and Methods for Modulating Cytokines
JP2025517969A (ja) 2022-05-25 2025-06-12 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 腫瘍抑制因子及び癌遺伝子の調節のための組成物及び方法
CA3253328A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and Modulation Methods of Genetic Drivers
US20250320254A1 (en) 2022-05-25 2025-10-16 Flagship Pioneering Innovations Vii, Llc Compositions and Methods for Modulating Circulating Factors
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
US20260098062A1 (en) 2022-09-21 2026-04-09 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
WO2024186695A2 (en) * 2023-03-03 2024-09-12 Trustees Of Boston University Immune cell fusion (icf) and uses thereof
EP4698665A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
EP4698666A1 (en) 2023-04-18 2026-02-25 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
KR20240154736A (ko) * 2023-04-18 2024-10-28 가톨릭대학교 산학협력단 면역관문 억제제의 표적화된 전달을 위한 세포외소포체의 용도
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
WO2025072667A2 (en) * 2023-09-29 2025-04-03 University Of Utah Research Foundation Compositions and methods for treating phosphomannomutase 2 (pmm2) deficiency
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025194138A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
CN120160961B (zh) * 2025-03-25 2026-02-03 北京大学第三医院（北京大学第三临床医学院） 一种全光谱流式检测细胞代谢的新探针组合及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150556A1 (en) * 2000-03-31 2002-10-17 Vile Richard G. Compositions and methods for tissue specific gene regulation therapy
US20110184049A1 (en) * 2008-04-22 2011-07-28 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
US20120121650A1 (en) * 2006-08-18 2012-05-17 Johnston Robert E Chimeric Virus Vaccines
CN103717240A (zh) * 2011-06-10 2014-04-09 蓝鸟生物公司 用于肾上腺脑白质营养不良症和肾上腺脊髓神经病的基因治疗载体
CN108138159A (zh) * 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US274651A (en) 1883-03-27 Advertising-windmill
US4623620A (en) 1983-08-02 1986-11-18 Stichting Vrienden Van De Stichting Dr. Karl Landsteiner Enucleated granulocytes, their preparation and use
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JPH10501403A (ja) 1994-03-04 1998-02-10 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 抗体−エンベロープ融合タンパク質および野生型エンベロープ融合タンパク質を含むレトロウィルスベクターを用いる細胞型特異的遺伝子移入
AU2589095A (en) 1994-05-16 1995-12-05 Washington University Cell membrane fusion composition and method
WO1997004748A2 (en) 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
PL332875A1 (en) 1996-10-17 1999-10-25 Oxford Biomedica Ltd Retroviral vectors
JPH10313865A (ja) 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
NZ509978A (en) 1998-09-23 2002-12-20 Austrian Nordic Biotherapeutic Removed particles protected against complement mediated destruction
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
DE60132436T2 (de) 2000-03-30 2008-04-17 Oxford Biomedica (Uk) Ltd. Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
WO2002002765A2 (en) 2000-07-05 2002-01-10 Transgene S.A. Chimeric promoters for controlling expression in smooth muscle cells
US6276394B1 (en) 2000-07-11 2001-08-21 General Valve, Inc. Compact stem set with load-balanced rollers for non-lubricated double block and bleed plug valves
CA2325088A1 (en) 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
ATE452972T1 (de) 2001-05-01 2010-01-15 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
CA2464887A1 (en) 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
ES2627445T3 (es) 2002-05-01 2017-07-28 Miltenyi Biotec Technology, Inc. Partículas de vector de lentivirus resistentes a la inactivación por el complemento
DE60335672D1 (de) 2002-05-14 2011-02-17 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus
CA2503317A1 (en) 2002-10-24 2004-05-06 Dnavec Research Inc. Method of transferring gene into t cells
PL377161A1 (pl) 2002-11-21 2006-01-23 Pevion Biotech Ltd. Wysoce efektywne pęcherzyki fuzogenne, sposób ich wytwarzania oraz kompozycje farmaceutyczne zawierające te pęcherzyki
US7842673B2 (en) 2003-12-17 2010-11-30 The Trustees Of Columbia University In The City Of New York Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
US20060045910A1 (en) 2004-09-02 2006-03-02 Ehringer William D Preserved fusogenic vesicles
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
JP2008518630A (ja) 2004-11-08 2008-06-05 イェール ユニバーシティ リボスイッチ、リボスイッチによる、構造を基礎とする化合物設計、ならびにリボスイッチの使用方法およびリボスイッチを伴う組成物
GB0426641D0 (en) 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
US8034331B2 (en) 2005-01-20 2011-10-11 Agency For Science, Technology And Research Method of delivery of nucleic acids to peripheral neurons
PT1881845E (pt) 2005-04-25 2010-05-31 Merial Ltd Vacinas de vírus nipah
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
WO2007005244A1 (en) 2005-07-05 2007-01-11 The Regents Of The University Of California Henipavirus receptor and uses thereof
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
WO2008071959A1 (en) 2006-12-12 2008-06-19 Oxford Biomedica (Uk) Limited Lentiviral vectors comprising micrornas
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
CN102264349A (zh) 2008-11-07 2011-11-30 儿童医院医疗中心 用于跨膜药物递送系统的鞘脂激活蛋白c以及相关蛋白和肽促融合性质
US9050269B2 (en) 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
JP5667180B2 (ja) 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
ES2455544T5 (es) 2009-07-24 2017-08-16 Immune Design Corp Vectores de lentivirus pseudotipificados con una glucoproteína de envoltura de virus sindbis
ES2693167T3 (es) 2009-11-13 2018-12-07 Inserm - Institut National De La Santé Et De La Recherche Médicale Administración directa de proteínas con microvesículas modificadas por ingeniería
US20120093885A1 (en) 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
CN103857387B (zh) 2011-06-02 2017-03-15 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
JP2013034401A (ja) 2011-08-04 2013-02-21 Gunma Univ アストロサイトで遺伝子を発現させるためのベクター
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP2615176A1 (en) 2012-01-11 2013-07-17 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells
WO2013148327A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Nipah virus envelope psuedotyped lentiviruses and methods of their use
EP2839032A4 (en) 2012-04-16 2015-11-18 Univ Texas PROOF OF EXCELLULAR JCV MIRNA
ES2686129T3 (es) 2012-11-13 2018-10-16 Codiak Biosciences, Inc. Administración de agentes terapéuticos
GB201313249D0 (en) 2013-07-25 2013-09-11 Isis Innovation Method
EA037503B1 (ru) 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
US9668147B2 (en) 2014-01-22 2017-05-30 Maxlinear, Inc. Autoconfigured backhaul transceiver
CA2945335A1 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
WO2016196350A1 (en) 2015-05-29 2016-12-08 New York University Auf1 encoding compositions for muscle cell uptake, satellite cell populations, and satellite cell mediated muscle generation
EP3322297B1 (en) 2015-07-13 2024-12-04 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10624849B2 (en) 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
US20170112773A1 (en) 2015-10-23 2017-04-27 Board Of Regents, The University Of Texas System Plasma membrane vesicles comprising functional transmembrane proteins
WO2017151717A1 (en) 2016-03-01 2017-09-08 French Brent A Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
IL261713B2 (en) 2016-03-19 2023-09-01 F1 Oncology Inc Methods and preparations for the transfer of lymphocytes and their regulated expansion
WO2017173034A1 (en) 2016-03-30 2017-10-05 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
WO2017173367A2 (en) 2016-03-31 2017-10-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
JP7072807B2 (ja) 2016-06-09 2022-05-23 アルマ・マテール・ストゥディオルム・ウニベルシータ・ディ・ボローニャ 細胞内増殖のための改変糖タンパク質ｈを有するヘルペスウイルス
CN109415698A (zh) 2016-06-16 2019-03-01 斯隆－凯特林纪念癌症中心 工程化Treg细胞
EP3472318B1 (en) 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US20180028600A1 (en) 2016-07-15 2018-02-01 Korea Institute Of Science And Technology Novel recombinant exosome and use thereof
KR20190053179A (ko) 2016-07-26 2019-05-17 센티 바이오사이언시스, 인코포레이티드 유전자 지우개들
JP7483373B2 (ja) 2016-07-29 2024-05-15 ジュノー セラピューティクス インコーポレイテッド 複製可能ウイルスの存在または非存在を評価するための方法
EP3540056A4 (en) 2016-11-10 2020-06-03 Kaneka Corporation METHOD FOR PRODUCING TRANSGENIC CELLS
AU2018206485B2 (en) 2017-01-09 2024-12-05 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
AU2018266111B2 (en) * 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US20210187018A1 (en) 2017-12-07 2021-06-24 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
AU2019269593A1 (en) 2018-05-15 2020-11-26 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
EP3880832A1 (en) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
SG11202105079QA (en) 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150556A1 (en) * 2000-03-31 2002-10-17 Vile Richard G. Compositions and methods for tissue specific gene regulation therapy
US20120121650A1 (en) * 2006-08-18 2012-05-17 Johnston Robert E Chimeric Virus Vaccines
US20110184049A1 (en) * 2008-04-22 2011-07-28 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
CN103717240A (zh) * 2011-06-10 2014-04-09 蓝鸟生物公司 用于肾上腺脑白质营养不良症和肾上腺脊髓神经病的基因治疗载体
CN108138159A (zh) * 2015-06-23 2018-06-08 费城儿童医院 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GLORIA GONZALEZ–ASEGUINOLAZA AND JESUS PRIETO: "Durable Correction of Inherited Metabolic Liver Disorders Requires Preventing Transgene Off-Targeting From Gene Therapy Vectors: The Value of MicroRNAs", EDITORIAL, vol. 139, no. 3, 23 July 2010 (2010-07-23), pages 728 *
MOHAMMAD KHALID ZAKARIA，ET AL: "Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells", BMC CANCER, vol. 14, no. 582, pages 2 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113960317A (zh) * 2021-08-19 2022-01-21 深圳市辅酶医科技有限公司 一种测量生物样品中nad+浓度的生物传感器及方法
CN113975285A (zh) * 2021-08-27 2022-01-28 南京大学 Ggpp结合并变构激活人源fbp1在制备抗肝细胞癌药物中的应用
WO2023024351A1 (zh) * 2021-08-27 2023-03-02 南京大学 Ggpp结合并变构激活人源fbp1在制备抗肝细胞癌药物中的应用
CN113969264B (zh) * 2021-11-29 2023-12-08 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN113969264A (zh) * 2021-11-29 2022-01-25 中南大学 Cog5基因敲除的人胚胎干细胞系、构建方法及应用
CN114292319A (zh) * 2021-12-31 2022-04-08 中国科学院遗传与发育生物学研究所 水稻ETFβ基因在调控植物育性中的应用
CN114292319B (zh) * 2021-12-31 2023-11-14 中国科学院遗传与发育生物学研究所 水稻ETFβ基因在调控植物育性中的应用
CN114875087A (zh) * 2022-04-27 2022-08-09 河北维达康生物科技有限公司 以β-吲哚基丙氨酸为底物合成5-羟基β-吲哚基丙氨酸的方法及其应用
CN114875087B (zh) * 2022-04-27 2023-08-04 河北维达康生物科技有限公司 以β-吲哚基丙氨酸为底物合成5-羟基β-吲哚基丙氨酸的方法及其应用
US12491266B2 (en) 2022-05-16 2025-12-09 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant AAV vectors for treating glutaric aciduria type I
CN119213133A (zh) * 2022-05-16 2024-12-27 上海天泽云泰生物医药有限公司 用于治疗i型戊二酸尿症的重组aav载体
CN115851632B (zh) * 2022-08-25 2024-04-26 华中农业大学 一种漆酶突变体及其应用
CN115851632A (zh) * 2022-08-25 2023-03-28 华中农业大学 一种漆酶突变体及其应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法
CN116970650A (zh) * 2023-09-22 2023-10-31 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法
WO2025256433A1 (zh) * 2024-06-14 2025-12-18 四川大学华西医院 一种转铁蛋白受体1靶向性糖苷水解酶复合体的制备方法及应用

Also Published As

Publication number Publication date
BR112021000145A2 (pt) 2021-04-06
SG11202100071YA (en) 2021-02-25
JP7588578B2 (ja) 2024-11-22
EP3820509A1 (en) 2021-05-19
KR20210043574A (ko) 2021-04-21
MX2021000308A (es) 2021-06-08
WO2020014209A1 (en) 2020-01-16
AU2019301053A1 (en) 2021-01-28
CA3105953A1 (en) 2020-01-16
US20210198698A1 (en) 2021-07-01
US20250369018A1 (en) 2025-12-04
JP2021530985A (ja) 2021-11-18
US12378578B2 (en) 2025-08-05
IL279897A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
US20250369018A1 (en) Fusosome compositions and uses thereof
JP7676305B2 (ja) Ｃｎｓ送達のためのフソソーム組成物
AU2019380517B2 (en) Fusosome compositions for hematopoietic stem cell delivery
JP7815327B2 (ja) フソソーム組成物およびその使用
US20230043255A1 (en) Fusosome compositions for t cell delivery
JP2025188163A (ja) ウイルスフソソームを産生するための方法及び組成物
CA3120103A1 (en) Fusosome compositions for t cell delivery
EP4590688A1 (en) Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
JP2026074096A (ja) Ｔ細胞送達のためのフソソーム組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210611